ArticlePharmaceuticals (Basel, Switzerland)2023
Selenylated Imidazo [1,2-
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Design, synthesis, biological evaluation, and in silico characterization of chalcone derivatives as antidiabetic hits.Scientific reports · 2026Article
- Cytotoxicity in vitro assay in 3D vs. 2D L929 cell cultures - comparative analysis of the response to the latex extracts.PloS one · 2026Article
- NaphthaleneACS omega · 2025Article
- Following the Trace of Cyclodextrins on the Selenium and Tellurium Odyssey.International journal of molecular sciences · 2024Review
- HPW-Catalyzed environmentally benign approach to imidazo[1,2-Beilstein journal of organic chemistry · 2024Article
- Applications of Pyrrole and Pyridine-based Heterocycles in Cancer Diagnosis and Treatment.Current pharmaceutical design · 2024Review
- Urea Hydrogen Peroxide and Ethyl Lactate, an Eco-Friendly Combo System in the Direct C(spACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Colon cancer incidence rates are increasing annually, a scenario aggravated by genetic and epigenetic alterations that promote drug resistance. Recent studies showed that novel synthetic selenium compounds are more efficient and less toxic than conventional drugs, demonstrating biocompatibility and pro-oxidant effects on tumor cells. This study aimed to investigate the cytotoxic effect of MRK-107, an imidazo [1,2-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.